Experience of prophylaxis treatment in children with severe haemophilia

被引:65
|
作者
Yee, TT
Beeton, K
Griffioen, A
Harrington, C
Miners, A
Lee, CA
Brown, SA
机构
[1] UCL Royal Free & Univ Coll Med Sch, Haemophilia Ctr, Dept Primary Care & Populat Sci, London NW3 2QG, England
[2] UCL Royal Free NHS Trust, Haemophilia Ctr, London, England
[3] UCL Royal Free NHS Trust, Haemostasis Unit, London, England
[4] Univ Hertfordshire, Hatfield AL10 9AB, Herts, England
关键词
haemophilia; prophylaxis; joint scores; Port-a-Cath; inhibitor;
D O I
10.1046/j.1365-2516.2002.00630.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The practice of prophylactic treatment of boys with severe haemophilia has been evaluated in our centre. Prophylaxis was started at the median age of 3.7 years (range 0.4-12.7 years) in 38/41 children (93%) under 17 years of age. Median follow-up was 4.1 years (range 0.4-12.7 years). The criteria of primary prophylaxis according to the definition by the European Paediatric Network of Haemophilia Management was fulfilled by 9/38 (24%). Although a majority [76%, 29/38] of the children started prophylaxis after a median number of joint bleeds of 3.5, 70% of the children in this group had clinical joint scores of 0. Intravenous catheter insertion was required at a median age of 15.5 months (range 5-36 months) in 21% of the children, resulting in a catheter infection rate of 1.74 per 1000 catheter days. None developed an inhibitor on prophylaxis and three patients who had low-titre inhibitors (< 5 Bethesda units) prior to prophylaxis had undetectable inhibitors after prophylaxis. The home-treatment training programme required considerable time and cost. As a result, 87% of the children used peripheral venous access and hospital visits declined as prophylaxis became established. Parents' incentives for prophylaxis were that the children undertook many physical activities and sports previously not recommended, there was less parental anxiety and an overall improvement in the quality of life for the whole family.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [41] EMICIZUMAB PROPHYLAXIS IN ADULT PATIENTS WITH SEVERE HAEMOPHLIA A INHIBITORS: EXPERIENCE FROM A GREEK HAEMOPHILIA CENTRE
    Kouraba, A.
    Zannou, A.
    Gotsi, S.
    Chanos, A.
    Pirpiri, T.
    Kelaidis, E.
    Katsarou, O.
    HAEMATOLOGICA, 2021, 106 (09) : 32 - 32
  • [42] Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A
    Dunn, A. L.
    Ahuja, S. P.
    Mullins, E. S.
    HAEMOPHILIA, 2018, 24 (03) : E84 - E92
  • [43] Evaluating the treatment of severe haemophilia A using cost-effectiveness measures in primary prophylaxis
    Axelsen, F.
    Miners, A.
    HAEMOPHILIA, 2011, 17 (02) : 364 - 365
  • [44] Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A
    Miners, A.
    HAEMOPHILIA, 2009, 15 (04) : 881 - 887
  • [45] AURIGA: study of adherence to prophylaxis in patients with severe haemophilia A
    Garcia-Dasi, M.
    Aznar, J. A.
    Jimenez Yuste, V
    Mingot, E.
    Lucia, F.
    Altisent, C.
    Jimenez, F.
    Lopez, F.
    Marco, P.
    Perez, R.
    Fernandez, A.
    Paloma, J.
    Galmes, B.
    Herrero, S.
    Garcia-Talavera, J. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 666 - 666
  • [46] Primary prophylaxis in severe haemophilia: which is the optimal regimen?
    Petrini, P.
    HAEMOPHILIA, 2009, 15 (02) : 624 - 624
  • [47] Auriga: study of adherence to prophylaxis in patients with severe haemophilia A
    Garcia Dasi, M.
    Aznar, J. A.
    Marco, P.
    Vila Gomez, C.
    Marco, A.
    HAEMOPHILIA, 2013, 19 : 62 - 62
  • [48] Severe haemophilia a: different regimens for starting prophylaxis (in PedNet)
    Nijdam, A.
    Petrini, P.
    Carcao, M.
    Kurnik, K.
    Auerswald, G.
    Nolan, B.
    Ljung, R.
    Molinari, A.
    Makipernaa, A.
    Fischer, K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 354 - 354
  • [49] Primary prophylaxis with rFVIIa in a patient with severe haemophilia a and inhibitor
    Jimenez-Yuste, Victor
    Quintana, Manuel
    Alvarez, Maria Teresa
    Martin-Salces, Monica
    Hernandez-Navarro, Fernando
    BLOOD COAGULATION & FIBRINOLYSIS, 2008, 19 (07) : 719 - 720
  • [50] A new paradigm for personalized prophylaxis for patients with severe haemophilia A
    Delavenne, Xavier
    Ollier, Edouard
    Lienhart, Anne
    Dargaud, Yesim
    HAEMOPHILIA, 2020, 26 (02) : 228 - 235